 | | Vol. 14.36 – 29 September, 2022 |
| |
|
|
| Investigators revealed that TGFB2-AS1 impaired the breast cancer stem-like cell traits of TNBC cells in vitro and dramatically decreases tumorigenic frequency and lung metastasis in vivo.
[Proceedings of the National Academy of Sciences of the United States of America] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors investigated the functional role of a novel long noncoding RNA SEMA3B-AS1 (lncRNA SEAS1) in breast cancer progression and the underlying mechanisms.
[Cell Death & Disease] |
|
|
|
| Researchers discovered a circRNA which encoded a novel protein, SEMA4B-211aa. Both circSEMA4B and SEMA4B-211aa were remarkably downregulated in breast cancer tissues and cell lines.
[Cell Death & Disease] |
|
|
|
| Scientists uncovered that HM13 was highly expressed in breast cancer and correlated with worse prognosis. Downregulation of HM13 could suppress breast cancer cell proliferation and metastasis abilities.
[Cell Death & Disease] |
|
|
|
| SNAI1 knockout cells exhibited plasticity in differentiation, drifting towards the luminal phenotype, gained stemness potential, and could differentiate into acinar mammospheres in 3D culture.
[Cell Death & Disease] |
|
|
|
| Researchers identified novel genomic alterations, including point mutations and genomic rearrangements at base-pair resolution.
[Breast Cancer Research] |
|
|
|
| The effect of β-escin on trastuzumab-resistant and -sensitive cell lines in vitro was evaluated for apoptosis, expression of HER2 family members, and impact on cancer stem cell-like properties.
[Cancer Cell International] |
|
|
|
| The authors investigated aflatoxin B1 (AFB1)-associated effects on human breast cancer cell lines, MCF-7, and found that AFB1 caused significant cytotoxicity on MCF-7 cells.
[Environmental Science and Pollution Research] |
|
|
|
|
| Investigators discuss the role of oncogenic RAS in controlling mechanical cell phenotypes, and how these mechanical changes promote oncogenic transformation in single cells and tissues.
[Trends in Cell Biology] |
|
|
|
| The authors discuss therapeutics targeting metastatic bresat cancer cells, bone cells, immune cells, and other stromal cells in the bone tumor microenvironment, including treatments that are currently used in the clinic, under development, and are potential new avenues for therapy.
[Pharmacology & Therapeutics] |
|
|
|
|
| The Cancer Research Society is awarding 90 new research grants valued at $10.8 million as part of its annual competition. It is an all-time record for the organization for a second year in a row. The grants are awarded to some of the most promising cancer research projects in Canada.
[Cancer Research Society] |
|
|
|
|
| November 7 -8, 2022
London, England, United Kingdom |
|
|
|
|
|
| | University of Oslo – Oslo, Norway |
|
|
|
| | AstraZeneca – Mississauga, Ontario, Canada |
|
|
|
| | Netherlands Cancer Institute (AVL) – Amsterdam, Netherlands |
|
|
|
| | Salk Institute – La Jolla, California, United States |
|
|
|
| | University of Sydney – Camperdown, Australia |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
